Innovative Blood Test Detects Multiple Sclerosis Risk Years Before Symptoms Manifest

A novel blood test developed by Vienna researchers can predict multiple sclerosis risk years before symptoms appear by detecting specific antibodies linked to Epstein-Barr virus infection, enabling early diagnosis and intervention.
Researchers at the Medical University of Vienna have developed a groundbreaking blood test capable of predicting the risk of developing multiple sclerosis (MS) long before clinical symptoms appear. This advancement could enable early intervention, potentially delaying or preventing disease onset. The study, recently published in Nature Communications, was led by Elisabeth Puchhammer-Stöckl and Hannes Vietzen from the Center for Virology, alongside Thomas Berger and Paulus Rommer from the Department of Neurology.
The new diagnostic approach centers on an immunological assay that detects specific antibodies targeting a protein from the Epstein-Barr virus (EBV), which is strongly associated with MS development. Nearly all MS cases have shown evidence of EBV infection, making it a key factor in the disease's pathology. The test specifically measures autoantibodies against EBNA-1, a component of EBV, which can cross-react with structures in the human brain. These autoantibodies appear within three years after EBV infection and are present even before symptoms begin.
By monitoring antibody levels over time, scientists found that individuals with consistently high levels of these antibodies are at a significantly increased risk of developing MS. The research involved analyzing blood samples from over 700 MS patients and more than 5,000 controls, some of whom could be traced back to the initial EBV infection. The findings indicated that high antibody levels correlate with rapid disease onset.
Multiple sclerosis is a chronic neuroinflammatory disorder affecting about 2.8 million people globally. It results from immune system attacks on the central nervous system, often triggered by EBV infection. Most individuals acquire EBV, usually asymptomatically or with infectious mononucleosis, but in some cases, the immune response misfires, leading to MS.
This new antibody test allows for immunological prediction of MS development years before any neurological symptoms, surpassing other markers like neurofilament light chain (NfL) or glial fibrillary acidic protein (GFAP), which only increase later in the disease process. Lead researcher Puchhammer-Stöckl emphasized that this could facilitate early diagnosis and treatment, potentially delaying or preventing the disease.
The team suggests that screening populations at higher risk—such as those with prior infectious mononucleosis—could be an effective approach. However, further research is necessary before implementing this as a routine clinical tool. Overall, the test represents a significant step towards proactive management of multiple sclerosis, focusing on early detection based on immune activity instead of waiting for symptoms to appear.
For more information, refer to the original study by Hannes Vietzen et al. in Nature Communications: [DOI: 10.1038/s41467-025-61751-9].
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Dual-Targeting Radiopharmaceutical Therapy Demonstrates Safety and Effectiveness in Treating Multiple Cancers
A new dual-targeting radiopharmaceutical therapy demonstrates high safety and effectiveness in treating various cancers, showing promising results in early human trials. This innovative approach offers hope for precision cancer treatment with minimal side effects.
Study Links Paternal Body Weight at Conception to Child Obesity Risk
New research highlights the crucial role of paternal body weight at conception in increasing the risk of obesity in children, emphasizing the importance of involving fathers in preconception health efforts.
Rethinking Abortion Laws: The Limitations of Fetal Viability Focus and Women's Real Experiences
This article examines how laws based on fetal viability often miss the mark in addressing women's real experiences and needs during pregnancy and abortion decisions.